Pfizer’s Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
Pfizer’s Hold Rating: Impact of Ponsegromab Trial Delays and Strategic Uncertainties
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...
BioSpace11d
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
cancerhealth16d
Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In?
In July, the Food and Drug Administration (FDA) approved the first blood test to use as primary screening for people at average risk for colon cancer. Called Shield, the test looks for the presence of ...